Erem, C. Et Al. 2009. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. EUROPEAN JOURNAL OF ENDOCRINOLOGY , vol.160, no.5 , 863-868.

Erem, C., KOÇAK, M., NUHOĞLU, İ., YILMAZ, M., & ÜÇÜNCÜ, Ö., (2009). Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. EUROPEAN JOURNAL OF ENDOCRINOLOGY , vol.160, no.5, 863-868.

Erem, CİHANGİR Et Al. "Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism," EUROPEAN JOURNAL OF ENDOCRINOLOGY , vol.160, no.5, 863-868, 2009

Erem, CİHANGİR Et Al. "Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism." EUROPEAN JOURNAL OF ENDOCRINOLOGY , vol.160, no.5, pp.863-868, 2009

Erem, C. Et Al. (2009) . "Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism." EUROPEAN JOURNAL OF ENDOCRINOLOGY , vol.160, no.5, pp.863-868.

@article{article, author={CİHANGİR EREM Et Al. }, title={Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism}, journal={EUROPEAN JOURNAL OF ENDOCRINOLOGY}, year=2009, pages={863-868} }